Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 3.500% 2/1
-
Market price (% of par)
-
102.91%
-
Total 13F principal
-
$111,223,000
-
Principal change
-
+$111,223,000
-
Total reported market value
-
$114,976,000
-
Number of holders
-
9
-
Value change
-
+$114,976,000
-
Number of buys
-
9
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.500% 2/1 as of Q3 2022
As of 30 Sep 2022,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.500% 2/1 was held by
9 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$111,223,000
in principal (par value) of the bond.
The largest 9 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ROYAL BANK OF CANADA, LAZARD ASSET MANAGEMENT LLC, COWEN AND COMPANY, LLC, Man Group plc, Bank of New York Mellon Corp, CITIGROUP INC, JPMORGAN CHASE & CO, and AMERICAN CENTURY COMPANIES INC.
This page lists
9
institutional bondholders reporting positions
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.